Evidence map›Paper›PMID 38907691›Full record

ArticleJournal of neurotrauma2024

Detecting and Predicting Cognitive Decline in Individuals with Traumatic Brain Injury: A Longitudinal Telephone-Based Study.

Jill Del Pozzo, Lisa Spielman, Belinda Yew, Danielle M Shpigel, Enna Selamanovic, Kristen Dams-O'Connor

Abstract read
In one paragraph

Article in Journal of neurotrauma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jill Del PozzoDepartment of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-4333-2331
Lisa SpielmanDepartment of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Belinda YewDepartment of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Danielle M ShpigelVA San Diego Healthcare System, San Diego, California, USA.
Enna SelamanovicGraduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kristen Dams-O'ConnorDepartment of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Funding

The Late Effects of TBI (LETBI) Study: Injury Patterns and Biological Markers of Post-Traumatic NeurodegenerationRF1NS115268 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Kristen Dams-O'Connor · 2019 to 2026
$10.3M
Mount Sinai Injury Control Research Center (MS-ICRC)R49CE002092 · CE · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GORDON, WAYNE A. · 2012 to 2018
$5.6M
Clinical & biological signatures of post-traumatic neurodegeneration: Leveraging the TBI Model Systems of Care to accelerate in vivo diagnosis of the late effects of TBI (LETBI)RF1NS128961 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DAMS-O'CONNOR, KRISTEN · 2022 to 2022
$5.0M
NCIPC CDC HHS R49 CE002092NINDS NIH HHS RF1 NS115268NINDS NIH HHS RF1 NS128961
6 · The paper itself

Abstract

Traumatic brain injuries (TBIs) can lead to long-lasting cognitive impairments, and some survivors experience cognitive decline post-recovery. Early detection of decline is important for care planning, and understanding risk factors for decline can elucidate targets for prevention. While neuropsychological testing is the gold standard approach to characterizing cognitive function, there is a need for brief, scalable tools that are capable of detecting clinically significant changes in post-TBI cognition. This study examines whether a clinically significant change can be detected using the Brief Test of Adult Cognition by Telephone (BTACT) in a sample of individuals with chronic TBI and investigates whether potentially modifiable factors are associated with cognitive decline. Ninety participants aged 40 or older with complicated mild-to-severe TBI participated in two telephone-based study visits ∼1 year apart. Demographic, head trauma exposure, comorbid medical conditions, physical, and psychosocial functioning data were collected via self-report. The BTACT, a brief measure of global cognitive function, was used to assess cognitive performance across six domains. A reliable change index for quantifying clinically significant changes in BTACT performance was calculated. Results revealed cognitive decline in 10-27% of participants across various cognitive domains. More specifically, only depressive symptoms, including depressed affect and anhedonia, were significantly associated with cognitive decline after correcting for multiple comparisons using false discovery rate (FDR). Other factors such as the number of blows to the head, male gender, dyspnea, increased anxiety symptoms, seizures, illicit drug use, and fewer cardiovascular comorbidities should be considered hypothesis generating. Importantly, age was not a significant predictor of cognitive decline, which challenges the assumption that cognitive decline is solely related to the natural aging process. It suggests that there are unique factors associated with TBI that impact cognitive function, and these factors can affect individuals across the lifespan. The BTACT is a brief and sensitive tool for identifying clinically meaningful changes in cognitive function over a relatively brief period (i.e., 1 year) in a sample of individuals in the chronic stages of TBI (i.e.,

Indexed as

Brain Injuries, TraumaticCognitive DysfunctionNeuropsychological TestsAdultAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedPredictive Value of TestsTelephoneBTACTcognitiondementiatraumatic brain injury

Identifiers

PMID38907691
PMCPMC11564846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.